-- Really "the best"? Or just good, on a disease that's easily treated? --> These patients were treated with the recombinant immunotoxin, BL22, which targets the CD22 cell surface receptor, which is highly expressed on these leukemic cells.
CD22 |
Bone marrow tumour cells express the following antigen targets CD20 (98.3%), CD22 (88.3%), CD40 (83.3%), CD52 (77.4%), IgM (83.3%), MUC1 core protein (57.8%), and 1D10 (50%).